Journals / Tüberküloz ve Toraks / 2020 / Cilt: 68 - Sayı: 2

The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer

Küçük hücreli dışı akciğer kanserinde yüksek PD-L1 düzeyi ile ilişkili klinikopatolojik faktörlerin ve periferik kan parametrelerinin belirlenmesi

Pages
118–125
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and systemicimmune-inflammmotry index were found significantly lower in PD-L1 ≥ 50%(p< 0.001, p= 0.006 and p= 0.003, respectively) and also negatively correlated with PD-L1 level (rho= -0.255, p< 0.001; rho= -0.17, p= 0.013; rho= -0.185, p= 0.006, respectively)Conclusion: According to the results of our study, peripheral blood parameters can be used to the prediction of the high PD-L1expression and can be used for reflection of current PD-L1 expression.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Programmed death ligand 1 (PD-L1) is a marker that widelyused for prediction of response to immunotherapy.
📊
Key Findings & Data:Dynamic alteration ofPD-L1 expression are the major problems for reflection of the actual status ofthe PD-L1.
💡
Conclusion & Impact:Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and systemicimmune-inflammmotry index were found significantly lower in PD-L1 ≥ 50%(p< 0.001, p= 0.006 and p= 0.003, respectively) and also negatively correlated with PD-L1 level (rho= -0.255, p< 0.001; rho= -0.17, p= 0.013; rho= -0.185, p= 0.006, respectively)Conclusion: According to the results of our study, peripheral blood parameters can be used to the prediction of the high PD-L1expression and can be used for reflection of current PD-L1 expression.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Programmed death ligand 1 (PD-L1) is a marker that widelyused for prediction of response to immunotherapy. Dynamic alteration ofPD-L1 expression are the major problems for reflection of the actual status ofthe PD-L1. So, we aimed to investigate the factors that may be associated withPD-L1 expression in lung cancer.Materials and Methods: The patients diagnosed with non-small cell lung cancer were enrolled, retrospectively. The patients were stratified according toPD-L1 expression level as ≥ 50% and < 50%.Results: Totally, 217 patients were enrolled. The clinicopathologic featureswere similar between two groups, except the amount of cigarette consumption. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and systemicimmune-inflammmotry index were found significantly lower in PD-L1 ≥ 50%(p< 0.001, p= 0.006 and p= 0.003, respectively) and also negatively correlated with PD-L1 level (rho= -0.255, p< 0.001; rho= -0.17, p= 0.013; rho= -0.185, p= 0.006, respectively)Conclusion: According to the results of our study, peripheral blood parameters can be used to the prediction of the high PD-L1expression and can be used for reflection of current PD-L1 expression.

Özet

Giriş: “Programmed death ligand 1 (PD-L1)” immünoterapilere yanıtı predikte etmek için yaygın olarak kullanılan bir belirteçtir. Bununla birlikte PD-L1 düzeyinin dinamik değişimi gerçek zamanlı PD-L1 düzeyinin yansıtılması için büyük bir problemdir. Bu sebeple bu çalışmada akciğer kanseri tanısı olan hastalarda PD-L1 düzeyi ile ilişkili olabilecek faktörlerin saptanması amaçlanmıştır. Materyal ve Metod: Küçük hücreli dışı akciğer kanseri tanısı olan hastalar retrospektif olarak çalışmaya dahil edildi. Hastalar PD-L1 ekspresyon düzeyine göre < %50 ve ≥ %50 olmak üzere ikiye ayrıldı. Bulgular: Toplam 217 hasta çalışmaya dahil edildi. Her iki grubun sigara tüketimi dışında klinikopatolojik özellikleri benzerdi. PD-L1 düzeyi ≥ %50 olan grupta nötrofil lenfosit oranı, platelet lenfosit oranı ve sistemik immün inflamatuvar indeks anlamlı olarak daha düşük saptandı (sırasıyla; p< 0.001, p= 0.006 ve p= 0.003). Aynı zamanda bu parametreler PD-L1 ekspresyon düzeyi ile negatif korele olarak saptandı (sırasıyla, rho= -0.255, p< 0.001; rho= -0.17, p= 0.013; rho= -0.185, p= 0.006). Sonuç: Bizim çalışma sonuçlarımıza göre periferal kan parametreleri PD-L1 düzeyini predikte etmek için kullanılabilir ve böylece güncel PD-L1 ekspresyon düzeyi yansıtılabilir

🔖

Cite This Article

AKYÜREK, N., ŞENDUR, M. A. N., BİLGİN, B., YÜCEL, Ş., YILMAZ, Ü., HIZAL, M., YALÇIN, B., AKINCI, M. B. (2022). The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer. Tüberküloz ve Toraks, Cilt: 68 - Sayı: 2, 118–125. https://ajindex.com/articles/618350

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34
  2. Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 2018;50:165
  3. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for firstline treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018;378:2288-301
  4. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:2078-92
  5. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-35
  6. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39
  7. Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol 2018;19:1468-79
  8. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379:2342-50
  9. Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 2018;362:k3529
  10. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823-33
  11. Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer 2018;17:129
  12. Kitano A, Ono M, Yoshida M, Noguchi E, Shimomura A, Shimoi T, et al. Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. ESMO Open 2017;2:e000150 13. Chang LC, Chen TP, Kuo WK, Hua CC. The protein expression of PDL1 is highly correlated with those of eIF2alpha and ATF4 in lung cancer. Dis Markers 2018;2018:5068701
  13. Chen Y, Zhang Y, Chai X, Gao J, Chen G, Zhang W, et al. Correlation between the expression of PD-L1 and clinicopathological features in patients with thymic epithelial tumors. Biomed Res Int 2018;2018:5830547. 15